Pfizer eyes $10B-plus market for RSV vaccines with two-prong approach

Aug. 28, 2022 12:00 PM ETPfizer Inc. (PFE)JNJ, GSK, SNY, BVNKF, SNYNF, BVNRY, MRNABy: Dulan Lokuwithana, SA News Editor22 Comments

Respiratory syncytial virus (RSV)

Artur Plawgo/iStock via Getty Images

Pfizer (NYSE:PFE) made a major step forward last week to access a market opportunity worth more than $10B for RSV vaccines as the pharma major seeks to replicate a pandemic-era business model against another

Recommended For You

Comments (22)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.